Pharmasset receives U.S. patent titled 'Nucleoside Phosphoramidate Prodrugs'

Pharmasset, Inc. (Nasdaq: VRUS) announces that the United States Patent and Trademark Office has issued U.S. patent 7,964,580 ("the '580 patent") titled "Nucleoside Phosphoramidate Prodrugs". This patent generally relates to the composition of matter of PSI-7977 and its diastereomeric mixture for the treatment of hepatitis C virus (HCV). PSI-7977, a uracil nucleotide analogue polymerase inhibitor of HCV, is being studied in multiple phase 2 trials.

"Today's announcement is a credit to our in-house research team in discovering new HCV product candidates," stated Schaefer Price, Pharmasset's President and Chief Executive Officer. "As the '580 patent is not due to expire until 2029, not including any patent term extension, it should become an important part of a growing portfolio of issued patents covering PSI-7977."

Source:

Pharmasset, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
New study aims to develop nucleoside therapy as treatment for mitochondrial depletion syndromes